Anne T Berg1, Susan R Levy, Francine M Testa, Hal Blumenfeld. 1. Department of Pediatrics, Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, U.S.A; the Northwestern Memorial Feinberg School of Medicine, Chicago, Illinois, U.S.A.
Abstract
OBJECTIVE: Examine the possible association between long-term seizure outcome in childhood absence epilepsy (CAE) and the initial treatment choice. METHODS: Children with CAE were prospectively recruited at initial diagnosis and followed in a community-based cohort study. Children presenting with convulsive seizures, significant imaging abnormalities, or who were followed <5 years were excluded. Early outcomes included success of initial medication, early remission, and pharmacoresistance. The primary long-term outcome was complete remission: ≥5 years both seizure free and medication free. Survival methods were used for analyses. RESULTS: The first medication was ethosuximde (ESM) in 41 (69%) and valproic acid (VPA) in 18 (31%). Initial success rates were 59% (ESM) and 56% (VPA). Early remission and pharmacoresistance were similar in each group. Apart from atypical electroencephalography (EEG) features (61% [VPA], 17% [ESM]), no clinical features varied substantially between the treatment groups. Complete remission occurred in 31 children (76%) treated with ESM and 7 (39%) who received VPA (p = 0.007). Children with versus without atypical EEG features were less likely to enter complete remission (50% vs. 71%, p = 0.03). In a Cox regression, ESM was associated with a higher rate of complete remission than VPA (hazards ratio [HR] 2.5, 95% confidence interval [CI] 1.1-6.0; p = 0.03). Atypical EEG features did not independently predict outcome (p = 0.15). Five-year and 10-year remission, regardless of continued treatment, occurred more often in children initially treated with ESM versus VPA. SIGNIFICANCE: These findings are congruent with results of studies in genetic absence models in rats and provide preliminary evidence motivating a hypothesis regarding potential disease-modifying effects of ESM in CAE. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here. Wiley Periodicals, Inc.
OBJECTIVE: Examine the possible association between long-term seizure outcome in childhood absence epilepsy (CAE) and the initial treatment choice. METHODS:Children with CAE were prospectively recruited at initial diagnosis and followed in a community-based cohort study. Children presenting with convulsive seizures, significant imaging abnormalities, or who were followed <5 years were excluded. Early outcomes included success of initial medication, early remission, and pharmacoresistance. The primary long-term outcome was complete remission: ≥5 years both seizure free and medication free. Survival methods were used for analyses. RESULTS: The first medication was ethosuximde (ESM) in 41 (69%) and valproic acid (VPA) in 18 (31%). Initial success rates were 59% (ESM) and 56% (VPA). Early remission and pharmacoresistance were similar in each group. Apart from atypical electroencephalography (EEG) features (61% [VPA], 17% [ESM]), no clinical features varied substantially between the treatment groups. Complete remission occurred in 31 children (76%) treated with ESM and 7 (39%) who received VPA (p = 0.007). Children with versus without atypical EEG features were less likely to enter complete remission (50% vs. 71%, p = 0.03). In a Cox regression, ESM was associated with a higher rate of complete remission than VPA (hazards ratio [HR] 2.5, 95% confidence interval [CI] 1.1-6.0; p = 0.03). Atypical EEG features did not independently predict outcome (p = 0.15). Five-year and 10-year remission, regardless of continued treatment, occurred more often in children initially treated with ESM versus VPA. SIGNIFICANCE: These findings are congruent with results of studies in genetic absence models in rats and provide preliminary evidence motivating a hypothesis regarding potential disease-modifying effects of ESM in CAE. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here. Wiley Periodicals, Inc.
Authors: Clemente Vega; Jennifer Guo; Brendan Killory; Nathan Danielson; Matthew Vestal; Rachel Berman; Leisel Martin; Jose L Gonzalez; Hal Blumenfeld; Marisa N Spann Journal: Epilepsia Date: 2011-06-02 Impact factor: 5.864
Authors: Brendan D Killory; Xiaoxiao Bai; Michiro Negishi; Clemente Vega; Marisa N Spann; Matthew Vestal; Jennifer Guo; Rachel Berman; Nathan Danielson; Jerry Trejo; David Shisler; Edward J Novotny; R Todd Constable; Hal Blumenfeld Journal: Neuroimage Date: 2011-03-21 Impact factor: 6.556
Authors: Tracy A Glauser; Avital Cnaan; Shlomo Shinnar; Deborah G Hirtz; Dennis Dlugos; David Masur; Peggy O Clark; Peter C Adamson Journal: Epilepsia Date: 2012-11-21 Impact factor: 5.864
Authors: Patrick Kwan; Alexis Arzimanoglou; Anne T Berg; Martin J Brodie; W Allen Hauser; Gary Mathern; Solomon L Moshé; Emilio Perucca; Samuel Wiebe; Jacqueline French Journal: Epilepsia Date: 2009-11-03 Impact factor: 5.864
Authors: Gabi Dezsi; Ezgi Ozturk; Davor Stanic; Kim L Powell; Hal Blumenfeld; Terence J O'Brien; Nigel C Jones Journal: Epilepsia Date: 2013-03-06 Impact factor: 5.864
Authors: Shlomo Shinnar; Avital Cnaan; Fengming Hu; Peggy Clark; Dennis Dlugos; Deborah G Hirtz; David Masur; Eli M Mizrahi; Solomon L Moshé; Tracy A Glauser Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Prince Antwi; Ece Atac; Jun Hwan Ryu; Christopher Andrew Arencibia; Shiori Tomatsu; Neehan Saleem; Jia Wu; Michael J Crowley; Barbara Banz; Federico E Vaca; Heinz Krestel; Hal Blumenfeld Journal: Epilepsy Behav Date: 2018-12-21 Impact factor: 2.937
Authors: Elliot Morse; Kathryn Giblin; Mi Hae Chung; Carolin Dohle; Anne T Berg; Hal Blumenfeld Journal: Epilepsy Res Date: 2019-02-25 Impact factor: 3.045
Authors: Avital Cnaan; Shlomo Shinnar; Ravindra Arya; Peter C Adamson; Peggy O Clark; Dennis Dlugos; Deborah G Hirtz; David Masur; Tracy A Glauser Journal: Neurology Date: 2016-12-16 Impact factor: 9.910